Bi-coastal research firm Abide Therapeutics recently appointed Sapna Srivastava as the company’s chief financial and strategy officer from its California hub, tapping her 15 years of expertise in both biopharmaceuticals and business.
Abide Therapeutics CEO and President Alan Ezekowitz conveyed the need to expand the company’s leadership sector at what he called “an exciting time in the life cycle of Abide Therapeutics,” describing Srivastava’s applicable background as highly compatible with the firm’s goals.
Previously, Srivastava served as chief financial and strategy officer at Intellia Therapeutics, assisting the firm in equity financing and transitioning to public ownership. Additionally, she worked on Wall Street for Goldman Sachs, Morgan Stanley and ThinkEquity Partners as a senior biotechnology analyst.
With a bachelor’s of science in biology from St. Xavier’s College at the University of Mumbai, Srivastava earned a doctorate in neuroscience from New York University’s School of Medicine.
“Abide is a remarkably unique combination of innovative science, world-class talent, and a company-wide shared commitment to positively impact the lives of people suffering from serious diseases,” Srivastava said. “I feel privileged to be part of the team and look forward to contributing to the significant advances being made by Abide.”
Abide runs offices in San Diego, California and Princeton, New Jersey.
